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Abstract
Gastrointestinal stromal tumors (GISTs) arise from the interstitial cells of Cajal
(ICCs) and are the most common mesenchymal neoplasm of the gastrointestinal
tract. While the majority of GISTs harbor activating mutations in either the
v-kit Hardy-Zuckerman feline sarcoma viral oncogene homolog (KIT) or plate-
let-derived growth factor receptor alpha (PDGFRA) tyrosine kinases, approxi-
mately 10–15% of adult GISTs and 85% of pediatric GISTs lack such
mutations. These “wild-type” GISTs have been reported to express high levels
of the insulin-like growth factor 1 receptor (IGF1R), and IGF1R-targeted ther-
apy of wild-type GISTs is being evaluated in clinical trials. However, it is not
clear that all wild-type GISTs express IGF1R, because studies to date have pre-
dominantly focused on a particular subtype of gastric wild-type GIST that is
deﬁcient in the mitochondrial succinate dehydrogenase (SDH) complex. This
study of a series of 136 GISTs, including 72 wild-type specimens, was therefore
undertaken to further characterize wild-type GIST subtypes based on the rela-
tive expression of transcripts encoding IGF1R. Additional transcripts relevant to
GIST biology were also evaluated, including members of the IGF-signaling
pathway (IGF1, IGF2, and insulin receptor [INSR]), neural markers (CDH2
[CDH: Cadherin], neuroﬁlament, light polypeptide, LHX2 [LHX: LIM homeo-
box], and KIRREL3 [KIRREL: kin of IRRE like]), KIT, PDGFRA, CD34, and
HIF1A. Succinate dehydrogenase complex, subunit B protein expression was
also assessed as a measure of SDH complex integrity. In addition to the previ-
ously described SDH-deﬁcient, IGF1R
high wild-type GISTs, other SDH-intact
wild-type subpopulations were deﬁned by high relative expression of IGF1R,
neural markers, IGF1 and INSR, or low IGF1R coupled with high IGF2. These
results underscore the complexity and heterogeneity of wild-type GISTs that
will need to be factored into molecularly-targeted therapeutic strategies.
Introduction
The identiﬁcation of activating mutations in the v-kit
Hardy-Zuckerman feline sarcoma viral oncogene homolog
(KIT) or platelet-derived growth factor receptor alpha
(PDGFRA) tyrosine kinases in ~85% of gastrointestinal
stromal tumors (GISTs) enabled the introduction of tar-
geted therapies that have proven much more effective
than traditional chemotherapy in the treatment of
advanced disease (reviewed in [1]). However, approxi-
mately 10–15% of adult GISTs and the majority of pedi-
atric GISTs lack KIT or PDGFRA mutations [2, 3]. These
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to kinase inhibitors than kinase-mutated GISTs [4–6].
This is signiﬁcant because up to 40% of GIST patients
will suffer disease recurrence after primary tumor re-
section [7]. A more comprehensive characterization of the
molecular GIST subtypes is therefore needed to advance
clinical management of GIST.
Approximately one-fourth of adult wild-type GISTs
and the majority of pediatric GISTs comprise a common
subtype of wild-type GIST. These occur most frequently
in females, arise in the stomach, are multinodular, and
exhibit epithelioid or mixed epithelioid and spindle-type
morphology [8]. The prognosis in these cases is not pre-
dicted by the standard criteria of size or mitotic rate, and
despite frequent lymph node metastases, these tumors run
an indolent course. These GISTs do not respond well to
imatinib, so that alternate therapeutic strategies are
needed [8, 9].
At the molecular level, this wild-type GIST sub-
population is characterized by loss of expression of the
mitochondrial succinate dehydrogenase (SDH) complex
and high expression of the insulin-like growth factor 1 recep-
tor (IGF1R). Mutational inactivation or loss of any SDH
component (A, B, C, or D) results in loss of the succinate
dehydrogenase complex, subunit B (SDHB) subunit, so
that SDHB immunohistochemistry may be used as a surro-
gate to identify these GISTs [10–20]. The SDH complex
converts succinate to fumarate. The succinate that accumu-
lates when SDH complex activity is impaired leads to
reduced turnover of hypoxia-induced factor 1 alpha
(HIF1Α) and heightened expression of HIF1A target genes
including vascular endothelial growth factor [21]. The
IGF1R tyrosine kinase is activated when the receptor binds
the ligands IGF1 or IGF2, triggering enhanced cell prolifer-
ation and survival through downstream activation of mito-
gen-activated protein kinase and PI3K-signaling pathways
[22]. IGF1R is highly expressed at both the RNA and protein
level in wild-type GISTs, and the receptor is acti-
vated, although not mutated in these tumors [23–29].
SDHB-deﬁcient, IGF1R
high GISTs may therefore be consid-
ered candidates for therapies targeting VEGFR and/or IGF1R.
SDH-deﬁcient, IGF1R
high wild-type GISTs may derive
from a common progenitor, and the cell of origin may
affect responses to targeted therapies. GISTs are hypo-
thesized to originate from either myenteric (ICC-MY) or
intramuscular (ICC-IM) interstitial cells of Cajal (ICCs)
[30]. In the mouse, early ICC progenitors have a
KIT
lowCD44
+CD34
+INSR
+IGF1R
+ phenotype, while
committed progenitors are KIT
highCD44
+CD34
+INSR
+IG
F1R
+, and mature ICCs are KIT
highCD44
+CD34
INSR
IGF1R
 [31, 32]. Unlike mature ICCs, the
KIT
lowCD44
+CD34
+ stem cells are resistant to KIT inhibi-
tion, even in the presence of an activating KIT mutation.
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The high IGF1R expression in the ICC progenitors suggests
that these may be the cells of origin of wild-type SDH-
deﬁcient, IGF1R
high GISTs. Indeed, SDH-deﬁcient wild-
type GISTs exhibit a gene expression pattern more closely
related to immature than mature ICCs, including high rela-
tive levels of IGF1R as well as several genes associated with
a neural phenotype [33].
While the molecular characterization of SDH-deﬁcient,
IGF1R
high wild-type GISTs has pointed the way toward
potential novel therapeutic strategies for this population,
it is not clear that these strategies would be applicable
broadly to all wild-type GISTs. In the case of IGF1R-
targeted therapy, for example, it has not been established
that all wild-type GISTs express IGF1R, nor that all
IGF1R
high GISTs are SDH deﬁcient. Heterogeneity among
wild-type GISTs could impact on their response to
IGF1R-targeted therapy.
Therefore, the goal of this study was to determine
whether wild-type GIST populations other than the well-
characterized SDH-deﬁcient IGF1R
high type could be
deﬁned by examining the expression of genes relevant to
GIST biology. The relative expression of transcripts encod-
ing IFG1R, additional members of the IGF-signaling path-
way, neural markers, KIT, PDGFRA, CD34, and HIF1A
was evaluated in a series of 72 wild-type tumors. An addi-
tional group of 64 KIT- or PDGFRA-mutant cases was
also included as a comparator. SDHB protein expression
was evaluated in 81 of these cases. In addition to the wild-
type SDH-deﬁcient, IGF1R
high population, distinct SDH-
intact wild-type GIST subpopulations were identiﬁed with
high relative expression of IGF1R, neural markers, IGF1
and insulin receptor (INSR), or low IGF1R combined with
high IGF2. These results demonstrate that there are several
wild-type GIST subtypes that may need to be considered
in the optimization of therapeutic strategies.
Materials and Methods
Tumor specimens and cDNA preparation
This study was conducted under full Institutional Review
Board (IRB) approval per federal and institutional guide-
lines. Blocks of formalin-ﬁxed, parafﬁn-embedded (FFPE)
tumor tissue, or unstained sections of FFPE tissue, were
obtained from the Pathology archives of the Oregon
Health and Science University, the Grupo Argentino de
Tumores Estromales Digestivos, Buenos Aires, Argentina,
and the Clinical Centre of Serbia, Belgrade. Wild-type
cases were selected from several population-based or ther-
apeutic intervention studies for which we received sam-
ples over the past 10 years. All wild-type cases with
sufﬁcient residual FFPE specimens for RNA extraction
were included in this study. Additional KIT- or
22 ª 2013 The Authors. Published by Blackwell Publishing Ltd.
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form a comparison group for the wild-type GIST cases.
KIT (exons 9, 11, 13, and 17) and PDGFRA (exons 12,
14, and 18) genotypes were previously determined as
described [2, 34]. Tumor-rich areas (90%) were
scraped from 5-lm unstained sections by comparison
with a hematoxylin and eosin–stained slide, and parafﬁn
was removed by incubation in Q solution (TrimGen,
Sparks, MD). Total RNA was extracted using a High Pure
FFPE RNA Micro kit (Roche, Indianapolis, IN). Single-
stranded cDNA was prepared from 1 lg of total RNA in
a 50-lL reaction using 60 lmol/L random hexamer prim-
ers, 0.5 mmol/L dNTPs, 100 units RNaseOUT, 5 mmol/L
DTT (DTT: dithiothreitol), 19 First Strand buffer, and
500 units SuperScript III reverse transcriptase following
manufacturer’s instructions (Invitrogen by Life Technolo-
gies, Grand Island, NY).
Real-time polymerase chain reaction
Real-time polymerase chain reaction (PCR) was carried out
in a 20-lL reaction using 2-lL single-stranded cDNA (cor-
responding to 40 ng initial total RNA) and 19 Probes Mas-
ter MIX (Roche), with a FAM-labeled hydrolysis probe
speciﬁc to the target of interest, and a Texas Red-labeled
probe speciﬁc to the reference Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). Cycling conditions on a Light-
Cycler 480 instrument (Roche) included 10 min at 95°C
followed by 40 cycles of 95°C for 10 sec and 60°C for
20 sec. Custom primers and hydrolysis probe were used to
detect a 66-bp GAPDH amplicon: GAPDH forward CAC-
TAGGCGCTCACTGTTCT, GAPDH reverse GCGAACT-
CCCCGTTG, GAPDH probe 5′TexRd-XN/TGGGGAAGG
TGAAGGTCGGA/3′IAbRQSp (IDT, Coralville, IA). Addi-
tional targets were detected using commercial TaqMan Gene
Expression assays (Applied Biosystems by Life Technologies):
IGF1R (64-bp amplicon) assay Hs00609566_m1, IGF1
(63 bp) Hs01547657_m1, IGF2 (81 bp) Hs01005963_m1,
INSR (76 bp) Hs00965956_m1, IRS1 (insulin receptor sub-
strate [IRS]) (69 bp) Hs00178563_m1, IRS2 (70 bp)
Hs00275843_s1, CDH2 [Cadherin (CDH)] (78 bp)
Hs00983062_m1, neuroﬁlament, light polypeptide (NEFL)
(71 bp) Hs00196245_m1, LHX2 (LIM homeobox [LHX])
(64 bp) Hs01104717_m1, KIRREL3 kin of IRRE like (KIR-
REL) (68 bp) Hs01123170_m1, CD34 (61 bp)
Hs00990730_m1, and HIF1A (62 bp) Hs00936371_m1.
Plasmid controls were used to conﬁrm that the assays were
linear over a series of template dilutions from 3 to 3 9 10
6
copies (linear regression R
2 0.98 for all assays). Plasmids
were prepared by cloning the PCR assay amplicons or were
obtained commercially. Commercial plasmids (OriGene,
Rockville, MD) included clones of IGF1 (RG215257), IGF2
(RC201849), INSR (RG215257), IRS1 (SC124032), CDH2
(SC119018), NEFL (SC116280), LHX2 (SC126761), KIRREL3
(SC100705), CD34 (SC302353), and HIF1A (SC119189).
Plasmid standards were also included in parallel with each
specimen test. The plasmid standards were used to calculate
the relative expression of each target as the ratio of copies of
the target of interest compared with copies of GAPDH.
Cluster analysis of relative gene expression proﬁles was
performed with Cluster 3.0, and results were visualized
with TreeView software [35]. Expression values were
log2-transformed and normalized, and cluster analysis was
performed with Self-Organizing Maps and a Euclidean
distance measure. A t-test was used to compare relative
gene expression levels between specimen groups across all
genes (Table S2).
SDHB immunohistochemistry
Sufﬁcient tissue was available from 81 specimens to evalu-
ate SDHB protein. SDHB protein expression was mea-
sured by immunohistochemistry with a monoclonal
mouse anti-SDHB antibody (1:100 dilution, clone
21A11AE7, Abcam, Cambridge, MA) on 4-lm-thick FFPE
whole-tissue sections following pressure cooker antigen
retrieval (0.001 mol/L citrate buffer, pH 6.0), as described
previously [15].
Results
IGF1R expression in molecularly and
clinically deﬁned GIST subtypes
To evaluate gene expression patterns in GIST subtypes, multi-
plex RT-PCR assays were used to measure the expression of a
s e r i e so ft a r g e tg e n e sr e l a t i v et ot h er e f e r e n c eg e n eG A P D H .
The assays employed a FAM-labeled probe to detect the target
of interest, and a Texas Red-labeled probe to measure GAP-
DH. To validate the approach, we ﬁrst measured relative KIT
and PDGFRA expression, expressed as the percent ratio rela-
tive to GAPDH. A series of 136 GISTs was evaluated that
included 52 KIT-mutant, 12 PDGFRA-mutant, 65 wild-type
GISTs arising in adults, and seven wild-type GISTs arising in
pediatric patients (Fig. 1). The relative KIT expression was
approximately threefold lower in PDGFRA-mutant compared
with KIT-mutant and wild-type GISTs (PDGFRA mutant vs.
KIT mutant P = 5 9 10
4,v s .a d u l tw i l dt y p eP = 9 9 10
3,
vs. pediatric wild type P = 2 9 10
2), while relative PDGFRA
expression was approximately 7- to 70-fold higher in PDG-
FRA-mutant GISTs compared with the other subtypes (PDG-
FRA mutant vs. KIT mutant P = 2 9 10
16,v s .a d u l tw i l d
type P = 2 9 10
8, vs. pediatric wild type P = 3 9 10
4).
These observations are consistent with previous reports of gene
expression proﬁling using microarray methodology [36], and
provide validation of the RT-PCR assays.
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IGF1R expression in GIST, we used a similar RT-PCR
assay to measure IGF1R relative to GAPDH. Measure-
ment of IGF1R mRNA by RT-PCR has been shown to
correlate with protein detection by immunohistochemistry
[37]. As shown in Figure 1, the mean relative IGF1R
expression was approximately 15- to 40-fold higher in
wild-type specimens compared with KIT- or PDGFRA-
mutant specimens, with highest expression in the pediat-
ric wild-type cases. The mean values in adult wild-type
(12.6  16.9) and pediatric wild-type GISTs
(17.5  16.3) were both signiﬁcantly higher than the val-
ues in KIT- (0. 5  0.5, P = 1 9 10
6 vs. adult wild type;
P = 7 9 10
11 vs. pediatric wild type) and PDGFRA-
mutant specimens (1.6  2.9; P = 2 9 10
2 vs. adult
wild type; P = 2 9 10
3 vs. pediatric wild type). These
results are consistent with previous reports of high rela-
tive IGF1R expression in adult and pediatric wild-type
GISTs [23, 26, 28, 29].
Expression patterns of members of the IGF-
signaling pathway, neural markers, CD34,
and HIF1A further deﬁne distinct GIST
subtypes
To further deﬁne the GIST subtypes, the expression of 11
other genes in addition to KIT, PDGFRA, and IGF1R was
also measured relative to GAPDH. The additional targets
included members of the IGF-signaling pathway (IGF1,
IGF2, INSR, IRS1, IRS2), neural markers (CDH2, LHX2,
NEFL, KIRREL3), as well as CD34 and HIF1A. Self-orga-
nizing cluster analysis revealed ﬁve cluster groups deﬁned
by the expression patterns of the 14 genes in the 136
GISTs (Fig. 2, Tables 1 and S2). The majority of wild-
type GISTs segregated into three clusters, two of which
exhibited high relative IGF1R expression and a third
which exhibited low IGF1R expression that is comparable
to KIT- and PDGFRA-mutant GISTs. The KIT-mutant
GISTs clustered in two main groups, one of which was
shared with wild-type GISTs. These two KIT-mutant
groups were distinguished from each other by differences
in CD34 expression. The majority of PDGFRA-mutant
GISTs clustered in one group deﬁned by high relative
PDGFRA, IGF1, and IRS1 expression.
The groups deﬁned by gene expression patterns were in
some cases paralleled by the location of the primary
tumors. For example, among 24 KIT-mutant tumors in
gene expression group 1, 16 originated in the small intes-
tine, while 12 of the 18 KIT-mutant tumors in gene
expression group 3 were from the stomach (Table S1).
High relative CD34 expression in the gastric GISTs was
one of the discriminators between the two KIT-mutant
groups, consistent with reports of high CD34 expression
in GISTs of the stomach versus small intestine [38, 39].
Among the adult wild-type GISTs, 19 tumors were located
in the stomach. Fifteen of these 19 specimens were clus-
tered in gene expression group 4, characterized by high
relative expression of IGF1R, neural markers, IGF1, and
INSR. The correlation of tumor location with gene expres-
sion proﬁles suggests that these gene expression patterns
may deﬁne biologically distinct GIST subtypes.
Wild-type GIST subtypes
The wild-type GISTs were predominantly clustered in
three groups that encompassed 65 of the 72 total wild-
type specimens. These included 59 adult and six pediatric
wild-type specimens (Fig. 2). Cluster groups 4 and 5
included 51 of the wild-type specimens and exhibited
high average relative IGF1R expression, while the average
relative IGF1R expression was approximately 25- to
40-fold lower in the 14 wild-type specimens of group 3
(group 3 vs. group 4: P = 3 9 10
4, group 3 vs. group 5:
P = 6 9 10
3). IGF1R expression in the IGF1R
low
wild-type group was comparable with that observed in
KIT- and PDGFRA-mutant cases (Table 1). Thus,
approximately one ﬁfth of the wild-type GISTs do not
express elevated levels of IGF1R.
The two wild-type GIST groups with high relative
IGF1R expression could be further discriminated from
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Figure 1. Relative KIT, PDGFRA, and IGF1R expression in KIT-mutant,
PDGFRA-mutant, and wild-type GISTs. Target gene expression was
measured in 138 GIST specimens by RT-PCR relative to the reference
GAPDH. Values are expressed as the percent ratio relative to GAPDH,
and depict the mean  standard deviation for each GIST subtype.
PDGFRA, platelet-derived growth factor receptor alpha; IGF1R, insulin-
like growth factor 1 receptor; GIST, gastrointestinal stromal tumor;
RT-PCR, real-time polymerase chain reaction.
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Figure 2. Gene expression clusters deﬁne GIST subtypes. Self-organizing cluster analysis of the relative expression of 14 target genes relative to
GAPDH identiﬁed ﬁve expression groups among 138 GIST specimens. Red indicates high relative expression and green indicates low relative
expression. Location of the primary tumor is listed as stomach, small intestine, other, or unknown. SDHB immunohistochemistry was performed
on 82 of the specimens, and was categorized as intact or deﬁcient, as indicated. KIT and PDGFRA mutation status are illustrated in blue or
orange, respectively, with nine indicating KIT exon 9 mutations. Pediatric specimens are indicated by arrows. GIST, gastrointestinal stromal tumor;
PDGFRA, platelet-derived growth factor receptor alpha.
Table 1. Target gene expression relative to GAPDH in GIST subtypes.
Gene
Heatmap cluster (genotype)
1 (KIT) 2 (PDGFRA) 3 (KIT) 3 (WT) 4 (WT) 5 (WT)
IGF1R 0.54  0.56 0.79  0.59 0.26  0.16 0.48  0.48 20  18 13  16
IGF1 0.42  0.51 8.2  5.5 0.48  0.67 0.41  0.36 1.8  1.7 3.1  5.8
IGF2 235  267 568  613 334  414 1680  1187 402  821 34  85
INSR 0.49  0.33 0.69  0.98 0.15  0.07 0.12  0.12 0.28  0.28 0.55  0.60
IRS1 1.2  2.3 12  10 0.73  1.0 1.1  1.5 1.2  2.4 1.8  2.3
IRS2 7.0  8.1 7.3  13.2 6.4  17.4 3.3  3.2 17  27 39  72
CDH2 0.53  0.74 0.050  0.053 0.89  2.1 0.82  1.3 5.8  4.3 11  17
LHX2 0.073  0.180 0.039  0.060 0.085  0.229 0.12  0.18 5.2  8.3 1.3  3.7
NEFL 0.059  0.167 0.023  0.037 0.028  0.078 1.6  4.2 8.0  13.7 2.8  6.9
KIRREL3 0.031  0.079 0.036  0.037 0.007  0.009 0.061  0.122 1.9  4.2 0.15  0.36
KIT 53  35 21  13 62  32 70  36 83  54 2.4  3.4
PDGFRA 0.28  0.35 26  15 2.5  3.2 3.4  6.3 0.76  1.5 1.5  1.5
CD34 4.6  4.2 24  15 73  39 84  61 62  69 10  13
HIF1 3.5  2.1 4.2  1.2 2.4  0.9 4.4  2.3 9.5  5.5 12.9  6.9
Values are expressed as the percent ratio of the target gene relative to GAPDH. Numbers are the mean  standard deviation. GIST, gastrointestinal
stromal tumor; PDGFRA, platelet-derived growth factor receptor alpha; WT, wild type; IGF1R, insulin-like growth factor 1 receptor; HIF1, hypoxia-
induced factor 1.
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low group by the elevated relative
expression of neural markers among the IGFIR
high GISTs
(Table 1). Mean relative CDH2 expression among the
wild-type GISTs in cluster group 4 was 6- and 100-fold
greater than in the KIT- or PDGFRA-mutant GISTs,
respectively (P < 7 9 10
5), and was similarly elevated in
the wild-type GISTs of cluster group 5 (P < 2 9 10
2 vs.
KIT mutant, P = 5 9 10
2 vs. PDGFRA mutant). In con-
trast, the mean relative CDH2 expression in the IGF1R
low
GISTS of group 3 was comparable with that of the KIT-
and PDGFRA-mutant cases, and was approximately
10-fold lower than in the IGF1R
high wild-type GISTs of
group 4 (P = 1 9 10
4) or group 5 (P = 4 9 10
2).
Similarly, LHX2 mean relative expression was approxi-
mately 15- to 130-fold higher in the wild-type GISTs of
cluster groups 4 and 5 compared with KIT- or PDGFRA-
mutant GISTs, or the wild-type IGF1R
low GISTS of group
3, although this difference only reached statistical signiﬁ-
cance in comparison with the wild-type GISTs of cluster
group 4 (P < 5 9 10
2). KIRREL3 mean relative expres-
sion was also higher in the wild-type IGF1R
high GISTs
than in the wild-type IGF1R
low or KIT- and PDGFRA-
mutant GISTs, although the difference only reached sta-
tistical signiﬁcance in the comparison of cluster group 4
and KIT-mutant GISTs (P = 4 9 10
2). Finally, NEFL
expression was highest in the wild-type GISTs of cluster
group 4, intermediate in the wild-type GISTs of cluster
groups 5 and 3, and lowest in the KIT- and PDGFRA-
mutant GISTs. These differences only reached statistical
signiﬁcance between the wild-type GISTs of cluster group
4 and the KIT-mutant GISTs (P < 3 9 10
2). Thus, in
the case of all four neural markers, there was either a
trend toward higher expression or a statistically signiﬁcant
elevation of mean relative expression in the IGF1R
high
GISTs compared with the IGF1R
low or KIT- and
PDGFRA-mutant GISTs.
Relative expression of members of the IGF-signaling
pathway further distinguished the wild-type GIST sub-
types (Table 1). The mean relative IGF1 expression was
approximately four- to eightfold higher in the IGF1R
high
wild-type GISTS of cluster groups 4 and 5 compared with
the IGF1R
low wild-type GISTs of cluster group 3 (group 4
vs. group 3: P = 5 9 10
3, group 5 vs. group 3:
P = 9 9 10
2). Similarly, INSR mean relative expression
was approximately two- to ﬁvefold higher in the
IGF1R
high wild-type GISTs compared with the IGF1R
low
wild-type GISTs (group 4 vs. group 3: P = 6 9 10
2,
group 5 vs. group 3: P = 8 9 10
3). In contrast, IGF2,
which was highly expressed in all cases, exhibited approxi-
mately 50-fold higher expression in the IGF1R
low GISTs
compared with the IGF1R
high GISTs of group 5
(P = 4 9 10
5) and approximately fourfold higher than
the IGF1R
high GISTs of group 4 (P = 7 9 10
5). While
mean relative IRS2 expression was approximately 5- to
10-fold higher in the IGF1R
high GISTs than the IGF1R
low
GISTs, the range of expression was broad, and the differ-
ences did not reach statistical signiﬁcance. IRS1 expres-
sion was not different among the wild-type GIST groups.
Hence, the wild-type GISTs with high IGF1R expression
exhibited higher IGF1 and INSR levels, while the wild-
type IGF1R
low GISTs expressed higher levels of IGF2.
HIF1A mean relative expression was approximately
two- to threefold higher in the IGF1R
high wild-type GISTs
of cluster groups 4 and 5 compared with the wild-type
IGF1R
low cluster 3 (P < 1 9 10
2) (Table 1). The KIT-
and PDGFRA-mutant GISTs were similar to the IGF1R
low
wild-type GISTs, and expressed approximately two- to
ﬁvefold lower relative HIF1A levels compared with the
IGF1R
high wild-type GISTs (P < 6 9 10
3).
While the expression of neural marker, IGF-signaling
pathway, and HIF1A genes was similar among the two
clusters of IGF1R
high wild-type GISTs, the two groups dif-
fered in the expression of KIT and CD34 (Table 1). Mean
relative KIT expression was approximately 35-fold higher
in the wild-type GISTs of group 4 compared with group
5( P = 3 9 10
6), and CD34 mean expression was
approximately sixfold higher in group 4 compared with
group 5 (P = 1 9 10
2). KIT and CD34 relative expres-
sion were comparable among the IGF1R
low wild-type
GISTs of group 3 and the wild-type GISTs of group 4.
Thus, relatively high KIT and CD34 expression distin-
guished the IGF1R
high group 4 wild-type GISTs from the
IGF1R
high group 5, and this high KIT and CD34 expres-
sion was shared with the wild-type IGF1R
low group 3
GISTs.
SDHB protein expression
Sufﬁcient tissue was available to measure SDHB protein
levels by immunohistochemistry in 81 of the 136 GISTs,
including 30 adult wild-type and one pediatric wild-type
specimen. Only four specimens were deemed SDHB deﬁ-
cient, and all four were wild-type tumors with gene
expression patterns that clustered in gene expression
group 4 (Fig. 2). Three of the SDHB-deﬁcient tumors
were located in the stomach, two arising in adults and
one in a pediatric patient. The fourth was a tumor
located in the omentum of an adult. The average age of
these four patients at the time of diagnosis was 33 years
(range 18–47). In comparison, there were 11 wild-type
GISTs in gene expression group 4 that exhibited intact
SDHB expression. Five of these tumors were located in
the stomach, three in the small intestine, one in the duo-
denum, and two of unknown location. The age at diagno-
sis was known for eight of these patients, and the average
was 44 years (range 17–66). The difference in average age
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was not signiﬁcant (P = 0.2).
Of the 14 genes analyzed, only IGF2 relative expression
exhibited a difference between SDHB-deﬁcient and
SDHB-intact wild-type specimens that reached statistical
signiﬁcance. The mean relative IGF2 level was 50  11 in
the four SDHB-deﬁcient specimens (range 38–59) and
160  113 in the 11 SDHB-intact wild-type specimens
(range 38–318; P = 0.04). In comparison, the mean rela-
tive IGF1R expression was high in both the SDHB-
deﬁcient wild-type GISTs (mean 11  9, range 4–23) and
the SDHB-intact specimens (mean 16  17, range 0.05–50,
P = 0.5). There was also no signiﬁcant difference in rela-
tive HIF1A expression between the SDHB-deﬁcient (mean
7  4, range 3–13) and SDHB-intact (mean 9  5, range
3–23) wild-type GISTs of expression group 4 (P = 0.2).
Thus, although the sample size was small, SDHB-deﬁcient
GISTs exhibited an approximately threefold lower relative
IGF2 expression level compared with SDHB-intact wild-
type GISTs. The SDHB-deﬁcient tumors expressed high
relative levels of IGF1R, but not all IGF1R
high wild-type
GISTs were SDHB deﬁcient.
KIT-mutant GIST subtypes
Forty-two of the KIT-mutant specimens clustered in two
groups, with 24 in group 1 and 18 in group 3. The latter
group was shared with 14 of the IGF1R
low wild-type GISTs
(Fig. 2, Table 1). Mean relative CD34 expression was
approximately 16-fold higher in the KIT-mutant GISTs of
group 3 compared with the KIT-mutant GISTs of group 1
(P = 3 9 10
10). The wild-type GISTs of group 3 had
similar levels of CD34 as the KIT-mutant specimens of
group 3, also 16-fold greater than that in the KIT-mutant
GISTs of group 1 (P = 3 9 10
7). Similarly, mean relative
PDGFRA expression was approximately 10-fold higher in
the KIT-mutant or wild-type GISTs of group 3 compared
with the KIT-mutant GISTs of group 1 (P < 2 9 10
2).
In contrast, mean relative INSR expression was approxi-
mately three- to fourfold higher in the KIT-mutant GISTs
of group 1 compared with either the KIT-mutant or wild-
type GISTs of group 3 (both P < 3 9 10
4). In addition,
ﬁve of eight KIT exon 9-mutant specimens segregated in
expression group 1, along with the majority of KIT-
mutant specimens localized in the small intestine. Thus,
the KIT-mutant GISTs of groups 1 and 3 could be dis-
criminated by higher relative expression of CD34 and
PDGFRA in group 3, and higher relative INSR expression
in group 1. The patterns of CD34, PDGFRA, and INSR
expression were shared between the wild-type and KIT-
mutant GISTs of group 3. The majority of KIT-mutant
GISTs in group 1 were located in the small intestine, while
those in group 3 were predominantly gastric.
PDGFRA-mutant GISTs
Of the 12 PDGFRA-mutant GISTs, 11 clustered in expres-
sion group 2 (Fig. 2, Table 1). These specimens were
characterized by mean relative PDGFRA expression that
was approximately 10- to 100-fold greater than that of
KIT-mutant or wild-type GISTs (P  3 9 10
5). The
PDGFRA-mutant GISTs also expressed mean relative lev-
els of IGF1 and IRS1 that were 5- to 20-fold higher than
that expressed in KIT-mutant or wild-type GISTs. In the
case of IGF1, these differences reached statistical signiﬁ-
cance in all comparisons of PDGFRA-mutant specimens
(P = 9 9 10
8 to 4 9 10
2). Differences in IRS1 expres-
sion between PDGFRA mutant and all other groups also
reached statistical signiﬁcance (P = 3 9 10
8 to
8 9 10
4). Hence, PDGFRA-mutant GISTs were charac-
terized by high relative expression of PDGFRA, IGF1, and
IRS1.
Discussion
Hierarchical cluster analysis of the relative expression of 14
genes relevant to GIST, including IGF1R, additional IGF-
signaling pathway genes, neural markers, HIF1A, KIT,
PDGFRA, and CD34, in 136 GISTs identiﬁed ﬁve distinct
expression groups. Wild-type GISTs were stratiﬁed into
three gene expression groups, including two with high rela-
tive IGF1R expression. SDHB protein expression was deﬁ-
cient in a subset of the IGF1R
high wild-type GISTs (Fig. 3a).
In comparison, the KIT-mutant GISTs were separated into
two groups, one of which was shared with IGF1R
low wild-
type GISTs (Fig. 3b), while PDGFRA-mutant GISTs were
categorized in a single group characterized by high relative
expression of PDGFRA, IGF1, and IRS1.
The 38 wild-type specimens within gene expression
group 4 exhibited high relative expression of IGF1R, neu-
ral markers, INSR, KIT, CD34, and IGF1, and low relative
IGF2. Four of these tumors were SDHB-deﬁcient GISTs,
which have been well characterized as gastric tumors with
multinodular epithelioid morphology and an indolent
clinical course [14, 15]. Eleven of the wild-type specimens
in this group 4 were SDHB intact (the others were not
tested), and included tumors in the stomach, small intes-
tine, and duodenum. Two other subtypes of wild-type
GIST were described by gene expression groups 3 and 5.
The former exhibited high relative mean expression of
KIT, CD34, and IGF2, with low relative IGF1R, INSR,
IGF1, and neural markers. This group likely corresponds
to a recently described population of adult wild-type
GISTs with high relative IGF2 expression and low IGF1R
expression [25]. Of note, high IGF2 is a poor prognostic
indicator for GIST [40]. The wild-type specimens in
expression group 5 showed a reciprocal pattern of low
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high relative expression of IGF1R, INSR, IGF1, and neural
markers. All 15 wild-type GISTs in groups 3 and 5 that
were tested for SDHB protein expression showed intact
SDHB.
In the case of SDHB protein deﬁciency, it has been pro-
posed that mitochondrial dysfunction may trigger elevated
IGF1R expression [41], potentially through a calcium- and
calcineurin-dependent mechanism [42]. This hypothesis is
consistent with the high level of IGF1R expression in pedi-
atric wild-type GIST, and the high prevalence of SDHB
deﬁciency in these tumors [13, 16, 23, 24, 26, 28, 29, 43,
44]. However, in the present series of 31 adult wild-type
GISTs screened for SDHB protein, 16 exhibited high rela-
tive IGF1R expression, but only three of these were SDHB
deﬁcient. Among these 16, six exhibited relative IGF1R
expression levels equal to or greater than the pediatric
wild-type GISTs, and all six of these possessed intact
SDHB protein. However, this does not preclude the possi-
bility that mitochondrial dysfunction caused by a mecha-
nism other than SDHB loss could trigger elevated IGF1R
expression in the SDHB-intact tumors.
Approximately 20% of the wild-type GISTs in the cur-
rent series did not exhibit elevated IGF1R expression. In the
absence of augmented IGF1R expression, IGF-signaling
pathways could potentially still be activated by elevated
expression of other components of the IGF1-
signaling pathway. For example, relative IGF2 expression
was elevated among the IGF1R
low wild-type GISTs
compared with the IGF1R
high wild-type GISTs. Inasmuch
as HIF1A is a transcriptional activator of IGF2 [45], a
positive correlation between HIF1A and IGF2 expression
might have been predicted. However, HIF1A expression
was approximately two- to threefold lower in the
IGF1R
low population compared with the IGF1R
high,
the reciprocal of the IGF2 expression pattern in these
populations.
The differential expression of IGF1R, as well as KIT,
CD34, and INSR among the wild-type GIST groups, may
reﬂect origins in distinct ICC populations. Detailed analy-
ses of ICC progenitors in the mouse have identiﬁed
KIT
lowCD34
+INSR
+IGF1R
+ stem cells, KIT
highCD34
+INS-
R
+IGF1R
+ committed progenitors, and mature ICCs with
a KIT
highCD34
INSR
IGF1R
 phenotype [31, 32].
Although the patterns of KIT, CD34, INSR, and IGF1R
expression observed in this study do not match the mur-
ine ICC proﬁles, it is possible that the expression patterns
of these markers differ between mouse and human, so
that they may deﬁne discrete cell populations of origin of
GISTs in humans. In addition, the KIT-mutant CD34
high-
INSR
low IGF1R
low GISTs shared gene expression group 3
with the wild-type CD34
high INSR
low IGF1R
low GISTs,
suggestive of possible commonalities of origin among
these tumors.
Collectively, the molecular subgroups of wild-type
GISTs deﬁned in this study are of interest, as they may
exhibit distinct clinical courses with differing sensitivities
to targeted therapies. In comparison with KIT-mutant
GISTs, the objective response to the kinase inhibitor
imatinib is signiﬁcantly lower among wild-type tumors
(44–45% vs. 70–71%) [4–6]. Of note, SDH-deﬁcient,
IGF1R
high gastric GISTs show essentially no response to
treatment with imatinib, but can respond to sunitinib [8,
9]. In addition, IGF1R-targeted therapy of wild-type GIST
is under investigation in clinical trials (e.g.,
NCT01560260), and the heterogeneity of IGF1R and IGF2
expression in the GIST groups may portend differential
responses. Finally, heterogeneity among cells of origin
IGF1R
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Neural
4 5 3
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wild-type
high high
low high high
low high high
KIT
CD34
low high high
low high high
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wild-type
4
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Expression group
IGF2 high low low low
low high high high
CD34
INSR
3
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3
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low
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Figure 3. Subpopulations of wild-type and KIT-mutant GISTs. (a) Adult wild-type GISTs are segregated into four groups based on the expression
levels of the IGF1R, neural marker, INSR, KIT, CD34 and IGF2 genes, and SDHB protein. Pediatric GISTs most closely resemble the adult wild-type
GISTs with high relative expression of IGF1R, neural markers, INSR, KIT, and CD34, and low relative expression of IGF2. SDHB protein was
detected in 16/19 IGF1R
high adult wild-type GISTs. (b) Some KIT-mutant GISTs exhibit similarities in relative CD34 and INSR expression compared
with adult wild-type IGF1R
low GISTs. GIST, gastrointestinal stromal tumor; IGF1R, insulin-like growth factor 1 receptor.
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murine GIST models [31]. Thus, the wild-type GIST
molecular subtypes described herein may represent
distinct clinical entities, so that their deﬁnition provides
the foundation for further studies that could provide
insights into improved tailored therapy and clinical man-
agement of GIST.
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